Literature DB >> 34661150

Cancer and COVID-19: On the Quest for Effective Vaccines.

Marwan Kwok1,2, Edward F Fritsch3,4, Catherine J Wu3,4,5,6.   

Abstract

Cancer vaccine development has been historically fraught with difficulty, but tremendous progress has been made over the past 5 years. In this In Focus article, we reflect on the progress and challenges with vaccine development for cancers in general and for hematologic malignancies in particular, and suggest how our cancer vaccine experience can offer insight into COVID-19 vaccination. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 34661150      PMCID： PMC8500734          DOI： 10.1158/2643-3230.BCD-20-0205

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  15 in total

1.  Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

Authors:  Derin B Keskin; Annabelle J Anandappa; Jing Sun; Itay Tirosh; Nathan D Mathewson; Shuqiang Li; Giacomo Oliveira; Anita Giobbie-Hurder; Kristen Felt; Evisa Gjini; Sachet A Shukla; Zhuting Hu; Letitia Li; Phuong M Le; Rosa L Allesøe; Alyssa R Richman; Monika S Kowalczyk; Sara Abdelrahman; Jack E Geduldig; Sarah Charbonneau; Kristine Pelton; J Bryan Iorgulescu; Liudmila Elagina; Wandi Zhang; Oriol Olive; Christine McCluskey; Lars R Olsen; Jonathan Stevens; William J Lane; Andres M Salazar; Heather Daley; Patrick Y Wen; E Antonio Chiocca; Maegan Harden; Niall J Lennon; Stacey Gabriel; Gad Getz; Eric S Lander; Aviv Regev; Jerome Ritz; Donna Neuberg; Scott J Rodig; Keith L Ligon; Mario L Suvà; Kai W Wucherpfennig; Nir Hacohen; Edward F Fritsch; Kenneth J Livak; Patrick A Ott; Catherine J Wu; David A Reardon
Journal:  Nature       Date:  2018-12-19       Impact factor: 49.962

2.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance.

Authors:  Vivek Verma; Rajeev K Shrimali; Shamim Ahmad; Winjie Dai; Hua Wang; Sumin Lu; Rahul Nandre; Pankaj Gaur; Jose Lopez; Moshe Sade-Feldman; Keren Yizhak; Stacey L Bjorgaard; Keith T Flaherty; Jennifer A Wargo; Genevieve M Boland; Ryan J Sullivan; Gad Getz; Scott A Hammond; Ming Tan; Jingjing Qi; Phillip Wong; Taha Merghoub; Jedd Wolchok; Nir Hacohen; John E Janik; Mikayel Mkrtichyan; Seema Gupta; Samir N Khleif
Journal:  Nat Immunol       Date:  2019-07-29       Impact factor: 25.606

3.  Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.

Authors:  Daniel K Wells; Marit M van Buuren; Kristen K Dang; Vanessa M Hubbard-Lucey; Kathleen C F Sheehan; Katie M Campbell; Andrew Lamb; Jeffrey P Ward; John Sidney; Ana B Blazquez; Andrew J Rech; Jesse M Zaretsky; Begonya Comin-Anduix; Alphonsus H C Ng; William Chour; Thomas V Yu; Hira Rizvi; Jia M Chen; Patrice Manning; Gabriela M Steiner; Xengie C Doan; Taha Merghoub; Justin Guinney; Adam Kolom; Cheryl Selinsky; Antoni Ribas; Matthew D Hellmann; Nir Hacohen; Alessandro Sette; James R Heath; Nina Bhardwaj; Fred Ramsdell; Robert D Schreiber; Ton N Schumacher; Pia Kvistborg; Nadine A Defranoux
Journal:  Cell       Date:  2020-10-09       Impact factor: 41.582

4.  An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma.

Authors:  Ugur Sahin; Petra Oehm; Evelyna Derhovanessian; Robert A Jabulowsky; Mathias Vormehr; Maike Gold; Daniel Maurus; Doreen Schwarck-Kokarakis; Andreas N Kuhn; Tana Omokoko; Lena M Kranz; Mustafa Diken; Sebastian Kreiter; Heinrich Haas; Sebastian Attig; Richard Rae; Katarina Cuk; Alexandra Kemmer-Brück; Andrea Breitkreuz; Claudia Tolliver; Janina Caspar; Juliane Quinkhardt; Lisa Hebich; Malte Stein; Alexander Hohberger; Isabel Vogler; Inga Liebig; Stephanie Renken; Julian Sikorski; Melanie Leierer; Verena Müller; Heidrun Mitzel-Rink; Matthias Miederer; Christoph Huber; Stephan Grabbe; Jochen Utikal; Andreas Pinter; Roland Kaufmann; Jessica C Hassel; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2020-07-29       Impact factor: 49.962

5.  Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8+ T cell responses.

Authors:  Anthony E Zamora; Jeremy Chase Crawford; E Kaitlynn Allen; Xi-Zhi J Guo; Jesse Bakke; Robert A Carter; Hossam A Abdelsamed; Ardiana Moustaki; Yongjin Li; Ti-Cheng Chang; Walid Awad; Mari H Dallas; Charles G Mullighan; James R Downing; Terrence L Geiger; Taosheng Chen; Douglas R Green; Benjamin A Youngblood; Jinghui Zhang; Paul G Thomas
Journal:  Sci Transl Med       Date:  2019-06-26       Impact factor: 17.956

6.  Strong vaccine responses during chemotherapy are associated with prolonged cancer survival.

Authors:  Cornelis J M Melief; Marij J P Welters; Ignace Vergote; Judith R Kroep; Gemma G Kenter; Petronella B Ottevanger; Wiebren A A Tjalma; Hannelore Denys; Mariette I E van Poelgeest; Hans W Nijman; Anna K L Reyners; Thierry Velu; Frederic Goffin; Roy I Lalisang; Nikki M Loof; Sanne Boekestijn; Willem Jan Krebber; Leon Hooftman; Sonja Visscher; Brent A Blumenstein; Richard B Stead; Winald Gerritsen; Sjoerd H van der Burg
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 17.956

7.  An immunogenic personal neoantigen vaccine for patients with melanoma.

Authors:  Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

8.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.

Authors:  Ugur Sahin; Evelyna Derhovanessian; Matthias Miller; Björn-Philipp Kloke; Petra Simon; Martin Löwer; Valesca Bukur; Arbel D Tadmor; Ulrich Luxemburger; Barbara Schrörs; Tana Omokoko; Mathias Vormehr; Christian Albrecht; Anna Paruzynski; Andreas N Kuhn; Janina Buck; Sandra Heesch; Katharina H Schreeb; Felicitas Müller; Inga Ortseifer; Isabel Vogler; Eva Godehardt; Sebastian Attig; Richard Rae; Andrea Breitkreuz; Claudia Tolliver; Martin Suchan; Goran Martic; Alexander Hohberger; Patrick Sorn; Jan Diekmann; Janko Ciesla; Olga Waksmann; Alexandra-Kemmer Brück; Meike Witt; Martina Zillgen; Andree Rothermel; Barbara Kasemann; David Langer; Stefanie Bolte; Mustafa Diken; Sebastian Kreiter; Romina Nemecek; Christoffer Gebhardt; Stephan Grabbe; Christoph Höller; Jochen Utikal; Christoph Huber; Carmen Loquai; Özlem Türeci
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

9.  Lenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccine.

Authors:  Caterina Lapenta; Simona Donati; Francesca Spadaro; Laura Lattanzi; Francesca Urbani; Iole Macchia; Paola Sestili; Massimo Spada; Maria Christina Cox; Filippo Belardelli; Stefano M Santini
Journal:  Cancer Immunol Immunother       Date:  2019-10-16       Impact factor: 6.968

10.  A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.

Authors:  Patrick A Ott; Siwen Hu-Lieskovan; Bartosz Chmielowski; Ramaswamy Govindan; Aung Naing; Nina Bhardwaj; Kim Margolin; Mark M Awad; Matthew D Hellmann; Jessica J Lin; Terence Friedlander; Meghan E Bushway; Kristen N Balogh; Tracey E Sciuto; Victoria Kohler; Samantha J Turnbull; Rana Besada; Riley R Curran; Benjamin Trapp; Julian Scherer; Asaf Poran; Dewi Harjanto; Dominik Barthelme; Ying Sonia Ting; Jesse Z Dong; Yvonne Ware; Yuting Huang; Zhengping Huang; Amy Wanamaker; Lisa D Cleary; Melissa A Moles; Kelledy Manson; Joel Greshock; Zakaria S Khondker; Ed Fritsch; Michael S Rooney; Mark DeMario; Richard B Gaynor; Lakshmi Srinivasan
Journal:  Cell       Date:  2020-10-15       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.